Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines

Blueprint Medicines Corporation (BPMC) reported a fourth-quarter 2023 loss of $1.82 per share, narrower than the Zacks Consensus Estimate of a loss of$2.04 and a loss of $2.65 in the year-ago quarter.Quarterly revenues of$72.0 million also surpassed the Zacks Consensus Estimate of $67.3 million. Revenues rose 85.5% year over year.Quarter in DetailBlueprint’s total revenues comprise net product revenues from Ayvakit/Ayvakyt and collaboration revenues.Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA pr ...